Saturday 17 October 2026 Export GANX’s income statement to Excel — free account

Gain Therapeutics, Inc.

Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.

1.26 0.07 −5.26%

Follow GANX

Alert me

Market cap: $58.1M
P/E: 0.0×
Fwd P/E: −2.4×
Dividend yield: —
F-score: 1/9
Altman Z: −1.79
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.21%

Capital & Financial Ratios $m

Market Cap 58.05

Revenue 0.20

Net Income (20.11)

Free Cash Flow (18.95)

Net Debt (12.74)

Current Ratio 4.36

Debt/Equity 0.03

P/E ratio 0.00

Fwd P/E (2.38)

P/S ratio 276.65

P/B ratio 4.78

Past 5Y EPS Growth —

This Y EPS Growth 18.55%

Next Y EPS Growth (31.04%)

Next Y revenue growth (27.54%)

Next 5Y EPS Growth (3.43%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 50.04%

10-year low 10-year high

P/B against its own 10 years 59.02%

10-year low 10-year high

EV/Sales against its own 10 years 53.39%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	17	10	21	13
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	0	0	0
	18	12	22	15

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	0	0	0	0
Other	2	2	2	2
	5	4	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	21.79%	24.07%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	24.52%	(0.56%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	0	—	—	—	0
’22	0	0	—	0	0
’21	0	0	0	0	0
’20	0	0	0	0	0
’19	—	—	—	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(4)	(5)	(5)	(5)	(18)
’24	(4)	(6)	(6)	(3)	(19)
’23	(4)	(5)	(4)	(6)	(19)
’22	(2)	(5)	(3)	(4)	(15)
’21	(3)	(3)	(2)	(4)	(12)
’20	(1)	0	(1)	(1)	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(4)	(5)	(5)	(5)	(18)
’24	(4)	(6)	(6)	(3)	(19)
’23	(4)	(5)	(4)	(6)	(19)
’22	(2)	(5)	(3)	(4)	(15)
’21	(3)	(3)	(2)	(4)	(12)
’20	(1)	0	(1)	(1)	(3)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.11)	—	—	—
’25	(0.16)	(0.19)	(0.15)	(0.11)	(0.61)
’24	(0.22)	(0.42)	(0.17)	(0.11)	(0.89)
’23	(0.43)	(0.62)	(0.37)	(0.29)	(1.71)
’22	(0.28)	(0.43)	(0.38)	(0.39)	(1.48)
’21	(0.50)	(0.30)	(0.39)	(0.25)	(1.37)
’20	(0.29)	(0.27)	(0.25)	(0.52)	(1.33)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	5.25	2.33	2.00	0.89	1.41	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	17.93	6.70	6.19	5.33	4.34
People
People	Employees	—	—	—	—	14	29	31	32	25	21
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	0	0	0	0	0	0	—	—
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	—	—	(1)	(2)	(4)	(14)	(17)	(22)	(20)	(19)
	EBT margin, %	—	—	(5,319.42)	(5,293.70)	(12,360.90)	(8,416.12)	(12,489.51)	(40,196.20)	0.00	0.00
	Net income	—	0	(1)	(2)	(4)	(14)	(18)	(22)	(20)	(20)
	Depreciation	—	—	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	0.01	0.02	0.01	0.02	0.01	0.00	0.00	0.00
	Earnings	—	—	(0.49)	(0.97)	(1.33)	(1.37)	(1.48)	(1.71)	(0.89)	(0.61)
	Cash flow	—	—	(0.33)	(0.83)	(1.21)	(1.22)	(1.24)	(1.45)	(0.82)	(0.56)
	Capex	—	—	0.00	(0.01)	(0.01)	(0.01)	(0.01)	0.00	0.00	0.00
	Free cash flow	—	—	(0.33)	(0.84)	(1.22)	(1.23)	(1.25)	(1.45)	(0.83)	(0.56)
	Book value	—	—	0.00	(0.20)	2.31	3.43	1.59	0.97	0.32	0.56
	Shares, m	—	—	2	2	3	10	12	13	23	33
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	P/S	—	—	1,039.00	1,039.00	1,039.00	334.52	210.04	241.83	—	—
	P/B	—	—	4.84	4.84	4.84	1.59	2.04	3.75	—	—
	EV/Sales	—	—	804.89	804.89	804.89	115.21	103.47	158.75	—	—
	EV/FCF	—	—	(7.13)	(7.13)	(7.13)	(1.53)	(1.28)	(1.64)	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(1)	(2)	(3)	(12)	(15)	(19)	(19)	(18)
	Capex	—	—	0	0	0	0	0	0	0	—
	Free cash flow	—	—	(1)	(2)	(3)	(12)	(15)	(19)	(19)	(18)
Balance, $m
Balance, $m	Working capital	—	—	—	0	7	35	17	13	8	19
	Total debt	—	—	—	0	1	1	1	1	0	0
	Net debt	—	—	—	0	(7)	(36)	(20)	(16)	(10)	(20)
	Shareholders’ equity	—	—	—	0	6	35	19	13	7	19
Returns, %
Returns, %	ROA	—	—	0.00	(664.36)	(69.71)	(57.18)	(55.77)	(104.28)	(132.83)	(115.39)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	0.00	(76.27)	(124.41)	(67.73)	(65.52)	(141.57)	(204.95)	(155.66)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Mar 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BMEA Biomea Fusion, Inc.	$60.6M	— (loss-making)	—	—	n/m	+47.80% (above 0%: growing)	0.00%	0.00%	Compare
PLRX Pliant Therapeutics, Inc.	$60.2M	— (loss-making)	— (loss-making)	−95.03% (below 0%: shrinking)	n/m	+68.61% (above 0%: growing)	0.00%	0.00%	Compare
XLO Xilio Therapeutics, Inc.	$59.4M	— (loss-making)	— (loss-making)	+131.22% (above 0%: growing)	n/m	−26.23% (below 0%: shrinking)	100.00%	(18.68%)	Compare
GANX Gain Therapeutics, Inc.	$58.1M	— (loss-making)	— (loss-making)	+27.78% (above 0%: growing)	n/m	+8.22% (above 0%: growing)	0.00%	0.00%
CNTB Connect Biopharma Holdings Limited Sponsored ADR	$57.1M	— (loss-making)	— (loss-making)	+296.56% (above 0%: growing)	n/m	−23.48% (below 0%: shrinking)	100.00%	(635.98%)	Compare
TENX Tenax Therapeutics, Inc.	$56.5M	— (loss-making)	—	−77.98% (below 0%: shrinking)	n/m	−125.93% (below 0%: shrinking)	0.00%	0.00%	Compare
ALPS Alps Group Inc.	$56.4M	— (loss-making)	—	—	n/m	−26.48% (below 0%: shrinking)	—	0.00%	Compare
ELOX Senesco Technologies Inc.	$55.3M	— (loss-making)	—	—	n/m	−144.34% (below 0%: shrinking)	100.00%	0.00%	Compare
GUTS Fractyl Health, Inc.	$55.2M	— (loss-making)	— (loss-making)	−57.14% (below 0%: shrinking)	n/m	+25.34% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$56.8M	—	—	−57.14%	—	−24.85%	100.00%	0.00%

All 614 Biotechnology stocks →

Gain Therapeutics, Inc. (GANX) key facts

Concern: Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022.
Gain Therapeutics, Inc. (GANX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GANX traded at $1.26, a market capitalization of $58.1 million.
Return on equity was −155.7% and debt-to-equity 0.03.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −1.79 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.